Please login to your online account to display your discounted pricing

Estrogen Receptor alpha Mouse anti-Human, Clone: tbykt, eBioscience™

Mouse Monoclonal Antibody

$143.55 - $375.55

Specifications

Antigen Estrogen Receptor alpha
Clone tbykt
Host Species Mouse
Gene Alias ERa
Species Reactivity Human
View More Specs

 Disclaimers

For Research Use Only.

Products
Catalog Number Mfr. No. Quantity Price Quantity    

501122807

 
affymetrix
14974080
25μg Each for $143.55

501122808

 
affymetrix
14974082
100μg Each for $375.55
Description & Specifications

Specifications

Antigen Estrogen Receptor alpha
Clone tbykt
Host Species Mouse
Gene Alias ERa
Species Reactivity Human
Applications Immunocytochemistry
Applications Immunohistochemistry
Applications Immunohistochemistry (Formalin/Paraffin)
Applications Western Blotting
Regulatory Status RUO
Conjugate Unlabeled
Format Purified
Storage Requirements Store at 2-8°C.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Concentration 0.5mg/mL

The tbykt monoclonal antibody reacts with the human Estrogen Receptor alpha (ERa) molecule. Estrogen receptor is a member of the superfamily of nuclear receptors, which are ligand-dependent transcription factors. The human estrogen receptor becomes activated following the binding of estrogen, causing a dissociation of the chaperone protein (Hsp90) and dimerization with either ERa or ERb. The alpha and beta receptors share some homology within their DNA- and ligand- binding domains, but signal in different ways and play different roles in gene regulation. Following activation, Era can directly bind to DNA through EREs (estrogen response elements) or through a more indirect pathway by binding to other transcription factors (Sp1, AP-1, NF-kB, FoxA1 and others). Era binding to DNA can either upregulate or repress gene expression. The alpha receptor has been implicated in the development and progression of breast cancer and its presence is indicative of improved survival and a better response to endocrine therapy (anti-estrogen therapy- tamoxifen).